Separate reporting around Zolgensma continues to emphasize the prescribing-label language on a theoretical tumorigenicity risk from AAV vector integration. Media coverage highlights patient and clinician concerns alongside Novartis statements that reported cases were promptly escalated to health authorities and that vector integration evidence is documented in at least two cases. For the biotech sector, this is a live example of post-authorization pharmacovigilance shaping clinical conversations for in vivo gene therapy. It also reinforces the importance of clear surveillance frameworks for late adverse events. The practical impact is that gene-therapy uptake and follow-up pathways may evolve as more integration-linked malignancy data accumulate across real-world populations.